Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

Phase 4 Completed 108 enrolled Yonsei University Daewoong Pharmaceutical Co. LTD. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI

Timeline

Start: 2022-12-01
Primary completion: 2025-02-05
Completion: 2025-02-05

Outcome

Met primary endpoint

paper At 2 weeks, LDL-C levels were lower in the evolocumab group compared to the non-evolocumab group (31±16 mg/dL vs. 63±17 mg/dL; p<0.001) PMID 41560483 ↗

Publications

Roh JW, Lee OH, Kim Y, Heo SJ, Im E, Cho DK. Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Korean Circ J. 2026 Apr;56(4):344-355. doi: 10.4070/kcj.2025.0315. Epub 2026 Jan 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Evolocumab	Monoclonal antibody	140 mg	Subcutaneous
Background	Ezetimibe	Unknown	10 mg	—
Background	Rosuvastatin	Small molecule	5 mg	—